Isoform-selective histone deacetylase inhibitors

Current Pharmaceutical Design

Volumn 14, Issue 6, 2008, Pages 529-544

  Itoh, Yukihiro ^a   Suzuki, Takayoshi ^a   Miyata, Naoki ^a  

^a NAGOYA CITY UNIVERSITY   (Japan)

Author keywords

HDAC inhibitors; Histone deacetylase; Isoform selective inhibitors; SIRT inhibitors

Indexed keywords

2 [1 (3 AMIDINOTHIOPROPYL) 1H INDOL 3 YL] 3 (1 METHYL 1H INDOL 3 YL)MALEIMIDE; 2 [1 (3 DIMETHYLAMINOPROPYL) 3 INDOLYL] 3 (3 INDOLYL)MALEIMIDE; AGK 2; AMIDOHYDROLASE INHIBITOR; ANTINEOPLASTIC AGENT; BUTYRIC ACID; CHLAMYDOCIN; EX 527; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; HR 73; HYDROXAMIC ACID; MEPYRAMINE MALEATE; MERCAPTOACETAMIDE DERIVATIVE; N (2 AMINOPHENYL) 4 (3 PYRIDINYLMETHOXYCARBONYLAMINOMETHYL)BENZAMIDE; N (2 AMINOPHENYL) 4 [4 (3 PYRIDINYL) 2 PYRIMIDINYLAMINOMETHYL]BENZAMIDE; NCH 51; NF 154; NF 259; NF 675; SB 379278A; SB 429201; SURAMIN; THIOLATE DERIVATIVE; TRAPOXIN A; TRAPOXIN B; TUBACIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALPROIC ACID; VORINOSTAT;

ACUTE GRANULOCYTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; B CELL LYMPHOMA; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; DRUG SCREENING; DRUG SELECTIVITY; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME LOCALIZATION; HODGKIN DISEASE; HUMAN; MYELODYSPLASTIC SYNDROME; NONHUMAN; PRIORITY JOURNAL; REVIEW; STRUCTURE ACTIVITY RELATION; T CELL LYMPHOMA;

ANIMALS; BINDING SITES; ENZYME INHIBITORS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HISTONE DEACETYLASES; HUMANS; ISOENZYMES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 42049118549     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161208783885335     Document Type: Review

References (180)

1. Jenuwein T, Allis CD. Translating the histone code. Science 2001; 293: 1074-90.
2. Hassig CA, Schreiber SL. Nuclear historic acetylases and deacetylases and transcriptional regulation: HATs off to HDACs. Curr Opin Chem Biol 1997; 1: 300-8.
3. Kouzarides T. Histone acetylases and deacetylases in cell proliferation. Curr Opin Genet Dev 1999; 9: 40-8.
4. Grozinger CM, Schreiber SL. Deacetylase enzymes: Biological functions and the use of small-molecule inhibitors. Chem Biol 2002; 9: 3-16.
5. Sambucetti LC, Fischer DD, Zabludoff S, Kwon PO, Chamberlin H, Trogani N, et al. Histone deacetylase inhibition selectively alters the activity and expression of cell cycle proteins leading to specific chromatin acetylation and antiproliferative effects. J Biol Chem 1999; 274: 34940-7.
6. Hirose T, Sowa Y, Takahashi S, Saito S, Yasuda C, Shindo N, et al. p53-independent induction of Gadd45 by histone deacetylase inhibitor: coordinate regulation by transcription factors Oct-1 and NF-Y. Oncogene 2003; 22: 7762-73.
7. Klisovic DD, Katz SE, Effron D, Klisovic MI, Wickham J, Parthun MR, et al. Depsipeptide (FR901228) inhibits proliferation and induces apoptosis in primary and metastatic human uveal melanoma cell lines. Invest Ophthalmol Vis Sci 2003; 44: 2390-8.
8. Sterner DE, Berger SL. Acetylation of histones and transcription-related factors. Microbiol Mol Biol Rev 2000; 64: 435-59.
9. Yoshida M, Shimazu T, Matsuyama A. Protein deacetylases: Enzymes with functional diversity as novel therapeutic targets. Prog Cell Cycle Res 2003; 5: 269-78.
10. Glozak MA, Sengupta N, Zhang X, Seto E. Acetylation and deacetylation of non-histone proteins. Gene 2005; 363: 15-23.
11. Konstantinopoulos PA, Karamouzis MV, Papavassilou AG. Focus on acetylation: The role of historic deacetylase inhibitors in cancer therapy and beyond. Expert Opin Investig Drugs 2007; 16: 569-71.
12. Yang XJ, Gregoire S. Clas II historic deacetylases: From sequence to function, regulation, and clinical implication. Mol Cell Biol 2005; 25: 2873-84.
13. Khochbin S, Verdel A, Lemercier C, Seigneurin-Berny D. Functional significance of histone deacetylase diversity. Curr Opin Genet Dev 2001; 11: 162-6.
14. de Ruijter AJ, van Gennip AH, Caton HN, Kemp S, van Kuilenburg AB. Historic deacetylases (HDACs): Characterization of the classical HDAC family. Biochem J 2003; 370: 737-49.
15. Murphy M, Ahm J, Walker KK, Hoffman WH, Evans RM, Levine AJ, et al. Transcriptional repression by wild-type p53 utilizes histone deacetylases, mediated by interaction with mSin3a. Genes Dev 1999; 13: 2490-501.
16. Fuks F, Burgers WA, Godin N, Kasai M, Kouzarides T. Dnmt3a binds deacetylases and is recruited by a sequence-specific repressor to silence transcription. EMBO J 2001; 20: 2536-44.
17. Juan LJ, Shia WJ, Chen MH, Yang WM, Seto E, Lin YS, et al. Histone deacetylases specifically down-regulate p53-dependent gene activation. J Biol Chem 2000; 275: 20436-43.
18. Ito A, Kawaguchi Y, Lai CH, Kovacs JJ, Higashimoto Y, Appella E, et al. MDM2-HDAC1-mediated deacetylation of p53 is required for its degradation. EMBO J 2002; 21: 6236-45.
19. WAF1 expression, independent of histone deacetylase 1. Cell Death Differ 2005; 12: 395-404.
20. Pal S, Yuri R, Datta A, Lacomis L, Erdjument-Bromage H, Kumar J, et al. mSin3A/histone deacetylase 2- and PRMT5-containing Brg1 complex is involved in transcriptional repression of the Myc target gene cad. Mol Cell Biol 2003; 23: 7475-87.
21. Guenther MG, Lane WS, Fischle W, Verdin E, Lazar MA, Shiekhattar R. A. core SMRT corepressor complex containing HDAC3 and TBL1, a WD40-repeat protein linked to deafness. Genes Dev 2000; 14: 1048-57.
22. Li J, Wang J, Wang J, Nawaz Z, Liu JM, Qin J, et al. Both corepressor proteins SMRT and N-CoR exist in large protein complexes containing HDAC3. EMBO J 2000; 19: 4342-50.
23. Wen YD, Perissi V, Staszewski LM, Yang WM, Krones A, Glass CK, et al. The histone-deacetylase-3 complex contains nuclear receptor corepressors. Proc Natl Acad Sci USA 2000; 97: 7202-7.
24. Waltregny D, de Leval L, Glénisson W, Ly Tran S, North BJ, Bellahcene A, et al. Expression of histon deacetylase 8, a class I histone deacetylase, is restricted to cells showing smooth muscle differentiation in normal human tissues. Am J Pathol 2004; 165: 553-64.
25. Waltregny D, Glenisson W, Tran SL, North BJ, Verdin E, Colige A, et al. Historic deacetylase HDAC8 associates with smooth muscle α-actin and is essential for smooth muscle cell contractility. FASEB J 2005; 19: 966-8.
26. Karamboulas C, Swedani A, Ward C, Al-Madhoun AS, Wilton S, Boisvenue S, et al. HDAC activity regulates entry of mesoderm cells into the cardiac muscle lineage. J Cell Sci 2006; 119: 4305-14.
27. Fischle W, Emiliani S, Hendzel MJ, Nagase T, Nomura N, Voelter W, et al. A new family of human histone deacetylases related to Saccharomyces cerevisiae HDAlp. J Biol Chem 1999; 274: 11713-20.
28. Giozinger CM, Hassig CA, Schreiber SL. Three proteins define a class of human histone deacetylases related to yeast Hdalp. Proc Natl Acad Sci USA 1999; 96: 4868-73.
29. Miska EA, Karlsson C, Langley E, Nielsen SJ, Pines J, Kouzarides T. HDAC4 deacetylase associates with and represses the MEF2 transcription factor. EMBO J 1999; 18: 5099-107.
30. Wang AH, Bertos NF, Vezmar M, Pelletier N, Crosato M, Heng HH, et al. HDAC4, a human histone deacetylase related to yeast HDA1, is a transcriptional corepressor. Mol Cell Biol 1999; 19: 7816-27.
31. Verdel A, Khochbin S. Identification of a new family of higher eukaryotic histone deacetylases. Coordinate expression of differentiation-dependent chromatin modifiers. J Biol Chem 1999; 274: 2440-5.
32. Spiegelberg BD, Hamm HE. Gβγ binds histone deacetylase 5 (HDAC5) and inhibits its transcriptional co-repression activity. J Biol Chem 2005; 280: 41769-76.
33. Hubbert C, Guardiola A, Shao R, Kawaguchi Y, Ito A, Nixon A, et al. HDAC6 is a microtubule-associated deacetylase. Nature 2002; 417: 455-8.
34. Matsuyama A, Shimazu T, Sumida Y, Saito A, Yoshimatsu Y, Seigneurin-Berny D, et al. In vivo destabilization of dynamic microtubules by HDAC6-mediated deacetylation. EMBO J 2002; 21: 6820-31.
35. Bali P, Pranpat M, Bradner J, Balasis M, Fiskus W, Guo F, et al. Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: A novel basis for antileukemia activity of histone deacetylase inhibitors. J Biol Chem 2005; 280: 26729-34.
36. Kovacs JJ, Murphy PJ, Gaillard S, Zhao X, Wu JT, Nicchitta CV, et al. HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor. Mol Cell 2005; 18: 601-7.
37. Hideshima T, Bradner JE, Wong J, Chauhan D, Richardson P, Schreiber SL, et al. Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma. Proc Natl Acad Sci USA 2005; 102: 8567-72.
38. Dressel HG, Bailey PJ, Wang SC, Downes M, Evans RM, Muscat GE. A dynamic role for HDAC7 in MEF2-mediated muscle differentiation. J Biol Chem 2001; 276: 17007-13.
39. Kasler HG, Verdin E. Histone deacetylase 7 functions as a key regulator of genes involved in both positive and negative selection of thymocytes. Mol Cell Biol 2007; 27: 5184-200.
40. Bakin RE, Jung MO. Cytoplasmic sequestration of HDAC7 from mitochondrial and nuclear compartments upon initiation of apoptosis. J Biol Chem 2004; 279: 51218-25.
41. Zhou X, Marks PA, Rifkind RA, Richon VM. Cloning and characterization of a histone deacetylase, HDAC9. Proc Natl Acad Sci USA2 2001; 98: 10572-7.
42. Méjat A, Ramond F, Bassel-Duby R, Khochbin S, Olson EN, Schaeffer L. Histone deacetylase 9 couples neuronal activity to muscle chromatin acetylation and gene expression. Nat Neurosci 2005; 8: 313-21.
43. Tong JJ, Liu J, Bertos NR, Yang XJ. Identification of HDAC10, a novel class II human histone deacetylase containing a leucine-rich domain. Nucleic Acids Res 2002; 30: 1114-23.
44. Voelter-Mahlknecht S, Ho AD, Mahlknecht U. Chromosomal organization and-localization of the novel class IV human histone deacetylase 11 gene. Int J Mol Med 2005; 16: 589-98.
45. Gregoretti IV, Lee YM, Goodson HV. Molecular evolution of the histone deacetylase family: Functional implications of phylogenetic analysis. J Mol Biol 2004; 338: 17-31.
46. Feng W, Lu Z, Luo RZ, Zhang X, Seto E, Liao WS, et al. Multiple historic deacetylases repress tumor suppressor gene ARHI in breast cancer. Int J Cancer 2007; 120: 1664-8.
47. Michishita E, Park JY, Burneskis JM, Barrett JC, Horikawa I. Evolutionarily conserved and nonconserved cellular localizations and functions of human SIRT proteins. Mol Biol Cell 2005; 16: 4623-35.
48. Frye RA. Phylogenetic classification of prokaryotic and eukaryotic Sir2-like proteins. Biochem Biophys Res Commun 2000; 273: 793-8.
49. Langley E, Pearson M, Faretta M, Bauer UM, Frye RA, Minucci S, et al. Human SIR2 deacetylates p53 and antagonizes PML/p53-induced cellular senescence. EMBO J 2002; 21: 2383-96.
50. Luo J, Nikolaev AY, Imai S, Chen D, Su F, Shiloh A, et al. Negative control of p53 by Sir2α promotes cell survival under stress. Cell 2001; 107: 137-48.
51. SIRTI functions as an NAD-dependent p53 deacetylase. Cell 2001; 107: 149-59.
52. Bereshchenko OR, Gu W, Dalla-Favera R. Acetylation inactivates the transcriptional repressor BCL6. Nat Genet 2002; 32: 606-13.
53. +-dependent tubulin deacetylase. Mol Cell 2003; 11: 437-44.
54. Inoue T, Hiratsuka M, Osaki M, Oshimura M. The molecular biology of mammalian SIRT proteins: SIRT2 in cell cycle regulation. Cell Cycle 2007; 6: 1011-8.
55. +-dependent histone deacetylase that translocates to the mitochondria upon cellular stress. Genes Dev 2007; 21: 920-8.
56. Schwer B, Bunkenborg J, Verdin RO, Andersen JS, Verdin E. Reversible lysine acetylation controls the activity of the mitochondrial enzyme acetyl-CoA synthetase 2. Proc Natl Acad Sci USA 2006; 103: 10224-9.
57. Shi T, Wang F, Stieren E, Tong Q. SIRT3, a mitochondrial sirtuin deacetylase, regulates mitochondrial function and thermogenesis in brown adipocytes. J Biol Chem 2005; 280: 13560-7.
58. Argmann C, Auwerx J. Insulin secretion: SIRT4 gets in on the act. Cell 2006; 126: 837-9.
59. Ahuja N, Schwer B, Carobbio S, Waltregny D, North BJ, Castronovo V, et al. Regulation of insulin secretion by SIRT4, a mitochondrial ADP-ribosyltransferase. J Biol Chem 2007; 282: 33583-92.
60. Mostoslavsky R, Chua KF, Lombard DB, Pang WW, Fischer MR, Gellon L, et al. Genomic instability and aging-like phenotype in the absence of mammalian SIRT6. Cell 2006; 124: 315-29.
61. Ford E, Voit R, Liszt G, Magin C, Grummt I, Guarente L. Mammalian Sir2 homolog SIRT7 is an activator of RNA polymerase I transcription. Genes Dev 2006; 20: 1075-80.
62. Leoni F, Zaliani A, Bertolini G, Porto G, Pagani P, Pozzi P, et al. The antitumor histone deacetylase inhibitor suberoylanilide hydroxamic acid exhibits antimflammatory properties via suppression of cytokines. Proc Natl Acad Sci USA 2002; 99: 2995-3000.
63. Dompierre JP, Godin JD, Charrin BC, Cordelieres FP, King SJ, Humbert S, et al. Histone deacetylase 6 inhibition compensates for the transport deficit in Huntington's disease by increasing tubulin acetylation. J Neurosci 2007; 27: 3571-83.
64. Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 2006; 5: 769-84.
65. Yoshida M, Horinouchi S, Beppu T. Trichostatin A and trapoxin: Novel chemical probes for the role of histone acetylation in chromatin structure and function. Bioessays 1995; 17: 423-30.
66. Yoshida M, Kijima M, Akita M, Beppu T. Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. J Biol Chem 1990; 265: 17174-9.
67. Richon VM, Webb Y, Merger R, Sheppard T, Jursic B, Ngo L, et al. Second generation hybrid polar compounds are potent inducers of transformed cell differentiation. Proc Natl Acad Sci USA 1996; 93: 5705-8.
68. Richon VM, Emiliani S, Verdin E, Webb Y, Breslow R, Rifkind RA, et al. A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. Proc Natl Acad Sci USA 1998; 95: 3003-7.
69. Grozinger CM, Chao ED, Blackwell HE, Moazed D, Schreiber SL. Identification of a class of small molecule inhibitors of the sirtuin family of NAD-dependent deacetylases by phenotypic screening. J Biol Chem 2001; 276: 38837-43.
70. + in the deacetylase activity of the SIR2-like proteins. Biochem Biophys Res Commun 2000; 278: 685-90.
71. Tervo AJ, Kyrylenko S, Niskanen P, Salminen A, Leppänen J, Nyrönen TH, et al. An in silico approach to discovering novel inhibitors of human sirtuin type 2. J Med Chem 2004; 47: 6292-8.
72. +-dependent deacetylases using phenotypic scr6ens in yeast. J Biol Chem 2003; 278: 52773-82.
73. Bedalov A, Gatbonton T, Irvine WP, Gottschling DE, Simon JA. Identification of a small molecule inhibitor of Sir2p. Proc Natl Acad Sci USA 2001, 98: 15113-8.
74. + dependent histone deacetylases (sirtuins) in ageing. Curr Drug Targets 2006; 7: 1553-60.
75. Hu E, Dul E, Sung CM, Chen Z, Kirkpatrick I, Zhang GF, et al. Identification of novel isoform-selective inhibitors within class I histone deacetylases. J Pharmacol Exp Ther 2003; 307: 720-8.
76. Fusetani N, Asai N, Matsunaga S, Honda K, Yasumuro K, Cyclostellettamines A-F, pyridine alkaloids which inhibit binding of methyl quinuclidinyl benzilate (QNB) to muscarinic acetylcholine receptors, from the marine sponge, Stelletta maxima. Tetrahedron Lett 1994; 35: 3967-70.
77. Oku N, Nagai K, Shindoh N, Terada Y, van Soest RW, Matsunaga S, et al. Three new cyclostellettamines, which inhibit histone deacetylase, from a marine sponge of the genus Xestospongia. Bioorg Med Chem Lett 2004; 14: 2617-20.
78. de Oliveira JH, Grube A, Köck M, Berlinck RG, Macedo ML, Ferreira AG, et al. Ingenamine G and cyclostellettamines G-I, K, and L from the new Brazilian species of marine sponge Pachychalina sp. J Nat Prod 2004; 67: 1685-9.
79. Pérez-Balado C, Nebbioso A, Rodríguez-Graña P, Minichiello A, Miceli M, Altucci L, et al. Bispyridinium dienes: histone deacetylase inhibitors with selective activities. J Med Chem 2007; 50: 2497-505.
80. Suzuki T, Ando T, Tsuchiya K, Fukazawa N, Saito A, Mariko Y, et al. Synthesis and histone deacetylase inhibitory activity of new benzamide derivatives. J Med Chem 1999; 42: 3001-3.
81. Beckers T, Burkhardt C, Wieland H, Gimmnich P, Ciossek T, Maier T, et al. Distinct pharmacological properties of second generation HDAC inhibitors with the benzamide or hydroxamate head group. Int J Cancer 2007; 121: 1138-48.
82. Vannini A, Volpari C, Filocamo G, Casavola EC, Brunetti M, Renzoni D, et al. Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor. Proc Natl Acad Sci USA 2004; 101: 15064-9.
83. Wang DF, Helquist P, Wiech NL, Wiest O. Toward selective histone deacetylase inhibitor design: Homology modeling, docking studies, and molecular dynamics simulations of human class I histone deacetylases. J Med Chem 2005; 48: 6936-47.
84. Haggarty SJ, Koeller KM, Wong JC, Grozinger CM, Schreiber SL. Domain-selective small-molecule inhibitor of historic deacetylase 6 (HDAC6)-mediated tubulin deacetylation. Proc Natl Acad Sci USA 2003; 100: 4389-94.
85. Saito A, Yamashita T, Mariko Y, Nosaka Y, Tsuchiya K, Ando T, et al. A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors. Proc Natl Acad Sci USA 1999; 96: 4592-7.
86. Furumai R, Matsuyama A, Kobashi N, Lee KH, Nishiyama M, Nakajima H, et al. FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases. Cancer Res 2002; 62: 4916-21.
87. Ueda H, Nakajima H, Hori Y, Fujita T, Nishimura M, Goto T, et al. FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. I. Taxonomy, fermentation, isolation, physico-chemical and biological properties, and antitumor activity. J Antibiot (Tokyo) 1994; 47: 301-10.
88. Ueda H, Manda T, Matsumoto S, Mukurnoto S, Nishigaki F, Kawamura I, et al. FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. III. Anti-tumor activities on experimental tumors in mice. J Antibiot (Tokyo) 1994; 47: 315-23.
89. Kano Y, Akutsu M, Tsunoda S, Izumi T, Kobayashi H, Mano H, et al. Cytotoxic effects of histone deacetylase inhibitor FK228 (depsipeptide, formally named FR901228) in combination with conventional anti-leukemia/ lymphoma agents against human leukemia/lymphoma cell lines. Invest New Drugs 2007; 25: 31-40.
90. Piekarz RL, Robey R, Sandor V, Bakke S, Wilson WH, Dahmoush L, et al. Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: A case report. Blood 2001; 98: 2865-8.
91. Byrd JC, Marcucci G, Parthun MR, Xiao JJ, Klisovic RB, Moran M, et al. A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia. Blood 2005; 105: 959-67.
92. Piekarz RL, Frye AR, Wright JJ, Steinberg SM, Liewehr DJ, Rosing DR, et al. Cardiac studies in patients treated with depsipeptide, FK228, in a phase II trial for T-cell lymphoma. Clin Cancer Res 2006; 12: 3762-73.
93. Yurek-George A, Cecil ARL, Mo AHK, Wen S, Rogers H, Habens F, et al. The first biologically active synthetic analogues of FK228, the depsipetide histone deacetylase inhibitor. J Med Chem 2007; 50: 5720-6.
94. Khan N, Jeffers M, Kumar S, Hackett C, Boldog F, Khramtsov N, et al. Determination of the class and isoform selectivity of small molecule HDAC inhibitors. Biochem J 2008; 409: 581-9.
95. Moradei OM, Mallais TC, Frechette S, Paquin I, Tessier PE, Leit S, et al. Novel aminophenyl benzamide-type histone deacetylase inhibitors with enhanced potency and selectivity. J Med Chem 2007; 50: 5543-6.
96. KrennHrubee K, Marshall BL, Hedglin M, Verdin E, Ulrich SM. Design and evaluation of 'Linkerless' hydroxamic acids as selective HDAC8 inhibitors. Bioorg Med Chem Lett 2007; 17: 2874-8.
97. Somozza JR, Skene RJ, Katz BA, Mol C, Ho JD, Jennings AJ, et al. Structural snapshots of human HDAC8 provide insights into the class I histone deacetylases. Structure 2004, 12: 1325-34.
98. Massa S, Mai A, Sbardella G, Esposito M, Ragno R, Loid' P, et al. 3-(4-Aroyl-1H-pyrrolyl-2-yl)-N-hydroxy-2-propenamides, a new class of synthetic historic deacetylase inhibitors. J Med Chem 2001; 44: 2069-72.
99. Mai A, Massa S, Ragno R, Esposito M, Sbardella G, Nocca G, et al. Binding mode analysis of 3-(4-benzoyl-1-methyl-1H-2-pyrrolyl)-N-hydroxy-2-propenamide: A new synthetic histone deacetylase inhibitor inducing histone hyperacetylation, growth inhibition, and terminal cell differentiation. J Med Chem 2002; 45: 1778-84.
100. Mai A, Massa S, Ragno R, Cerbara I, Jesacher F, Loidl P, et al. 3-(4-Aroyl-1-methyl-1H-2-pyrrolyl)-N-hydroxy-2-alkylamides as a new class of synthetic histone deacetylase inhibitors. I. Design, synthesis, biological evaluation, and binding mode studies. J Med Chem 2003; 46: 512-24.
101. Mai A, Massa S, Cerbara I, Valente S, Ragno R, Bottoni P, et al. 3-(4-Aroy1-methyl-1H-2-pyrrolyl)-N-hydroxy-2-alkylamides as a new class of synthetic histone deactylase inhibitors. 2. Effect of pyrrole C2 and/or C4 substitutions on biological activity. J Med Chem 2004; 47: 1098-109.
102. Ragno R, Mai A, Massa S, Cerbara I, Valente S, Bottoni P, et al. 3-(4-Aroyl-1-methyl-1H-pyrrol-2-yl)-N-hydroxy-2-alkylamides as a new class of synthetic histone deacetylase inhibitors. 3. Discovery of novel lead compounds through structure-based drug design and docking studies. J Med Chem 2004; 47: 1351-9.
103. Lusser A, Brosch G, Loidl A, Haas H, Loidl P. Identification of maize histone deacetylase HD2 as an acidic nucleolar phosphoprotein. Science 1997; 277: 88-91.
104. Kölle D, Brosch G, Lechner T, Pipal A, Helliger W, Taplick J, et al. Different types of maize histone deacetylases are distinguished by a highly complex substrate and site specificity. Biochemistry 1999;38: 6769-73.
105. Lechner T, Lusser A, Pipal A, Brosch G, Loidl A, Goralik-Schramel M, et al. RPD3-Types histone deacetylaces in maize embryos. Biochemistry 2000; 39: 1683-92.
106. Brosch G, Goralik-Schramel M, Loidl P. Purification of histone deacetylase HD1-A of germinating maize embryos. FEBS Lett 1996; 393: 287-91.
107. Brosch G, Georgieva EI, Lopez-Rodas G, Linder H, Loidl P. Specificity of Zea mays histone deacetylase is regulated by phosphorylation. J Biol Chem 1992; 267: 20561-4.
108. Mai A, Massa S, Pezzi R, Rotili D, Loidl P, Brosch G. Discovery of (aryloxopropenyl)pyrrolyl hydroxamides as selective inhibitors of class IIa histone deacerylase homologue HD1-A. J Med Chem 2003; 46: 4826-9.
109. Mai A, Massa S, Pezzi R, Simeoni S, Rotili D, Nebbioso A, et al. Class II (IIa)-selective historic deacetylase inhinitors. 1. Synthesis and biological evaluation of novel (aryloxopropenyl)pyrrolyl hydroxamides. J Med Chem 2005; 48: 3344-53.
110. Ragno R, Simeoni S, Rotili D, Caroli A, Botta G, Brosch G, et al. Class II-selective histone deacetylase inhinitors. Part 2: Alignment-independent GRIND 3-D QSAR, homology and docking studies. Eur J Med Chem 2007; in press (doi:l0.t016/j.ejmech.2007.05. 004).
111. Sternson SM, Wong JC, Grozinger CM, Schreiber SL. Synthesis of 7200 small molecules based on a substructural analysis of the histone deacetylase inhibitors trichostatin and trapoxin. Org Lett 2001; 3: 4239-42.
112. Haggarty SJ, Koeller KM, Wong JC, Butcher RA, Schreiber SL. Multidimensional chemical genetic analysis of diversity-oriented synthesis-derived deacetylase inhibitors using cell-based assays. Chem Biol 2003; 10: 383-96.
113. Wong, JC, Hong R, Schreiber SL. Structural biasing elements for in-cell histone deacetylase paralog selectivity. J Am Chem Soc 2003; 125: 5586-7.
114. Herman D, Jenssen K, Burnett R, Soragni E, Perlman SL, Gottesfeld JM. Histone deacetylase inhibitors reverse gene silencing in Friedreich's ataxia. Nat Chem Biol 2006; 2: 551-8.
115. Campuzano V, Montermini L, Moltò MD, Pianese L, Cossée M, Cavalcanti F, et al. Friedreich's ataxia: Autosomal recessive disease caused by an intronic GAA triplet repeat expansion. Science 1996; 271: 1423-7.
116. Bidichandani SI, Ashizawa T, Patel PI. The GAA triplet-repeat expansion in Friedreich ataxia interferes with transcription and may be associated with an unusual DNA structure. Am J Hum Genet 1998; 62: 111-21.
117. Watson J, Glasg MB. Butyric acid in the treatment of cancer. Lancet 1933; 221: 746-8.
118. Chen JS, Faller DV, Spanjaard RA. Short-chain fatty acid inhibitors of histone deacetylases: Promising anticancer therapeutics? Curr Cancer Drug Targets 2003; 3: 219-36.
119. Johannessen CU. Mechanisms of action of valproate: A commentatory. Neurochem Int 2000; 37: 103-10.
120. Tunnicliff G. Actions of sodium valproate on the central nervous system. J Physiol Pharmacol 1999; 50: 347-65.
121. Phiel CJ, Zhang F, Huang EY, Guenther MG, Lazar MA, Klein PS. Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J Biol Chem 2001; 276: 36734-41.
122. Gottlicher M, Minucci S, Zhu P, Kramer OH, Schimpf A, Giavara S, et al. Valproic acid defines a novel class of HDAC inhibitors including differentiation of transformed cells. EMBO J 2001; 20: 6969-78.
123. Gurvich N, Tsygankova OM, Meinkoth JL, Klein PS. Histone deacetylase is a target of valproic acid-mediated cellar differentiation. Cancer Res 2004; 64: 1079-86.
124. Kaiser M, Zavrski I, Sterz J, Jakob C, Fleissner C, Kloetzel PM, et al. The effects of the histone deacetylase inhibitor valproic acid on cell cycle, growth suppression and apoptosis in multiple myeloma. Haematologica 2006; 91: 248-51.
125. McLaughlin F, La Thangue NB. Historic deacetylase inhibitors open new doors in cancer therapy. Biochem Pharmacol 2004; 68: 1139-44.
126. Candelaria M, Gallardo-Rincón D, Arce C, Cetina L, Aguilar-Ponce J, Arrieta O, et al. A phase II study of epigenetic therapy with hydralazine and magnesium valproate to overcome chemotherapy resistance in refractory solid tumors. Ann Oncol 2007; 18: 1529-38.
127. Itazaki H, Nagashima K, Sugita K, Yoshida H, Kawamura Y, Yasuda Y, et al. Isolation and structural elucidation of new cyclotetrapeptides, trapoxin A and B, having detransformation activities as antitumor agents. J Antibiot (Tokyo) 1990; 43: 1524-32.
128. Hirota A, Suzuki A , Suzuki H, Tamura S. Isolation and biological acrtivity of Cyl-2 of ametabolite of Cylindrocladium scoparium. Agric Biol Chem 1973; 37: 643-7.
129. Hirota A, Suzuki A, Aizawa K, Tamura S. Structure of Cyl-2, a novel cyclotetrapeptide from Cylindrocladium scoparium. Agric Biol Chem 1973; 37: 955-6.
130. Stähelin H, Trippmacher A. Cytostatic activity of chlamydocin, a rapidly inactivated cyclic tetrapeptide. Eur J Cancer 1974; 10: 801-8.
131. Kijima M, Yoshida M, Sugita K, Horinouchi S, Beppu T. Trapoxin, an antitumor cyclic tetrapeptide, is an irreversible inhibitor of mammaliam histone deacetylase. J Biol Chem 1993; 268: 22429-35.
132. Brosch G, Ransom R, Lechner T, Walton JD, Loidl P. Inhibition of maize historic deacetylases by HC toxin, the host-selective toxin of Cochliobolus carbonum. Plant Cell 1995; 7: 1941-50.
133. de Schepper S, Bruwiere H, Verhulst T, Steller U, Andries L, Wouters W, et al. Inhibition of historic deacetylases by chlamydocin induces apoptosis and proteasome-mediated degradation of survivin. J Pharmacol Exp Ther 2003; 304: 881-8.
134. Furumai R, Komatsu Y, Nishino N, Khochbin S, Yoshida M, Horinouchi S. Potent histone deacetylase inhibitors built from trichostatin A and cyclic tetrapeptide antibiotics including trapoxin. Proc Natl Acad Sci USA 2001; 98: 87-92.
135. Suzuki T, Nagano Y, Matsuura A, Kohara A, Ninomiya S, Kohda K, et al. Novel historic deacetylase inhibitors: Design, synthesis, enzyme inhibition, and binding mode study of SAHA-based nonhydroxamates. Bioorg Med Chem Lett 2003; 13: 4321-6.
136. Suzuki T, Kouketsu A, Matsuura A, Kohara A, Ninomiya S, Kohda K, et al. Thiol-based SAHA analogues as potent histone deacetylase inhibitors. Bioorg Med Chem Lett 2004; 14: 3313-7.
137. Suzuki T, Nagano Y, Kouketsu A, Matsuura A, Maruyama S, Kurotaki M, et al. Novel inhibitors of human histone deacetylases: Design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxamates. J Med Chem 2005; 48: 1019-32.
138. Suzuki T, Hisakawa S, Itoh Y, Maruyama S, Kurotani M, Nakagawa H, et al. Identification of a potent and stable antiproliferative agent by the prodrug formation of a thiolate histone deacetylase inhibitor. Bioorg Med Chem 2007; 17: 1558-61.
139. Suzuki T, Hisakawa S, Itoh Y, Suzuki N, Takahashi K, Kawahata M, et al. Design, synthesis, and biological activity of folate receptor-targeted prodrugs of thiolate histone deacetylase inhibitors. Bioorg Med Chem Lett 2007; 17: 4208-12.
140. Suzuki T, Matsuura A, Kouketsu A, Hisakawa S, Nakagawa H, Miyata N. Design and synthesis of non-hydroxamate histone deacetylase inhibitors: identification of a selective histone acetylating agent. Bioorg Med Chem 2005; 13: 4332-42.
141. Sanda T, Okamoto T, Uchida Y, Nakagawa H, Iida S, Kayukawa S, et al. Proteome analyses of the growth inhibitory effects of NCH-51, a novel histone deacetylase inhibitor, on lymphoid malignant cells. Leukemia 2007; 21: 2344-53.
142. Zou H, Wu Y, Navre M, Sang BC. Characterization of the two catalytic domains in historic deacetylase 6. Biochem Biophys Res Commun 2006; 341:45-50.
143. Saji S, Kawakami M, Hayashi S, Yoshida N, Hirose M, Horiguchi S, et al. Significance of RDAC6 regulation via estrogen signaling for cell motility and prognosis in estrogen receptor-positive breast cancer. Oncogene 2005; 24: 4531-9.
144. Suzuki T, Matsuura A, Kouketsu A, Nakagawa H, Miyata N. Identification of a potent non-hydroxamate histone deacetylase inhibitor by mechanism-based drug design. Bioorg Med Chem Lett 2005; 15: 331-5.
145. Chen B, Petukhov PA, Jung M, Velena A, Eliseeva E, Dritschilo A, et al. Chemistry and biology of mercaptoacetamides as novel histone deacetylase inhibitors. Bioorg Med Chem Lett 2005; 15: 1389-92.
146. Anandan SK, Ward JS, Brokx RD, Bray MR, Patel DV, Xiao XX. Mercaptoamide-based non-hydroxamic acid type histone deacetylase inhibitors. Bioorg Med Chem Lett 2005; 15: 1969-72.
147. Kozikowski AP, Chen Y, Gaysin A, Chen B, D'Annibale MA, Suto CM, et al. Functional differences in epigenetic modulators-superiority of mercaptoacetamide-based histone deacetylase inhibitors relative to hydroxamates in cortical neuron neuroprotection studies. J Med Chem 2007; 50: 3054-61.
148. Morrison BE, Majdzadeh N, Zhang X, Lyles A, Bassel-Duby R, Olson EN, et al. Neuroprotection by histone deacetylase-related protein. Mol Cell Biol 2006; 26: 3550-64.
149. Heltweg B, Dequiedt F, Marshall BL, Branch C, Yoshida M, Nishino N, et al. Subtype selective substrates for histone deacetylases. J Med Chem 2004; 47: 5235-43.
150. Suzuki T, Kouketsu A, Itch Y, Hisakawa S, Maeda S, Yoshida M, et al. Highly potent and selective histone deacetylase inhibitors design based on a small-molecular substrate. J Med Chem 2006; 49: 4809-12.
151. Itoh Y, Suzuki T, Kouketsu A, Suzuki N, Maeda S, Yoshida M, et al. Design, synthesis, structure-selectivity relationship, and effect on human cancer cells of a novel series of histone deacetylase 6-selective inhibitors. J Med Chem 2007; 50: 5425-38.
152. Fiskus W, Ren Y, Mohapatra A, Bali P, Mandawat A, Rao R, et al. Hydroxamic acid analogue histone deacetylase inhibitors attenuate estrogen receptor-α levels and transcriptional activity: A result of hyperacetylation and inhibition of chaperone function of heat shock protein 90. Chn Cancer Res 2007; 13: 4882-90.
153. Napper AD, Hixon J, McDonagh T, Keavey K, Pons JF, Barker J, et al. Discovery of indoles as potent and selective inhibitors of the deacetylase SIRT1. J Med Chem 2005; 48: 8045-54.
154. Bitterman KJ, Anderson RM, Cohen HY, Latorre-Esteves M, Sinclair DA. inhibition of silencing and accelerated aging by nicotinamide, a putative negative regulator of yeast Sir2 and human SIRT1. J Biol Chem 2002; 277: 45099-107.
155. Solorrion JM, Pasupuleti R, Xu L, McDonagh T, Curtis R, DiStefano PS, et al. Inhibition of SIRT1 catalytic activity increases p53 acetylation but does not alter cell survival following DNA damage. Mol Cell Biol 2006; 26: 28-38.
156. Hawking F, Suramin: With special reference to onchocerciasis. Adv Pharmacol Chemother 1978; 15: 289-322.
157. Voogd TE, Vansterkenburg EL, Wilting J, Janssen LH. Recent research on the biological activity of suramin. Pharmacol Rev 1993; 45: 177-203.
158. Howitz KT, Bitterman KJ, Cohen HY, Lamming DW, Lavu S, Wood JG, et al. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature 2003; 425: 191-6.
159. +-dependent histone deacetylases (sirtuins). ChemMedChem 2007; 2: 1419-31.
160. Pagans S, Pedal A, North BJ, Kaehlcke K, Marshall BL, Dorr A, et al. SIRT1 regulates HIV transcription via Tat deacetylation. PLoS Biol 2005; 3: E41.
161. +-dependent histone deacetylases, from kinase to sirtuin inhibition. J Med Chem 2006; 49: 7307-16.
162. Suzuki T, Imai K, Nakagawa H, Miyata N. 2-Anilinobenzamides as SIRT inhibitors. ChemMedChem 2006; 1: 1059-62.
163. Davies SP, Reddy H, Caivano M, Cohen P. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J 2000; 351: 95-105.
164. Outeiro, TF, Kontopoulos E, Altmann SM, Kufareva I, Strathearn KE, Amore AM, et al. Sirtuin 2 inhibitors rescue α-synuclein-mediated toxicity in models of Parkinson's disease. Science 2007; 317: 516-9.
165. Finnin MS, Donigian JR, Pavletich, NP. Structure of the histone deacetylase SIRT2. Nat Struct Biol 2001; 8: 621-5.
166. Kiviran PH, Leppänen J, Rinne VM, Suuronen T, Kyrylenko O, Kyrylenko S, et al. N-(3-(4-Hydroxyphenyl)-propenoyl)-amino acid tryptamides as SIRT2 inhibitors. Bioorg Med Chem Lett 2007, 17, 2448-51.
167. Tervo AJ, Suuronen T, Kyrylenko S, Kuusisto E, Kiviranta PH, Salminen A, et al . Discovering inhibitors of human sirtuin type 2: Novel structural scaffolds. J Med Chem 2006; 49: 7239-41.
168. Heltweg B, Gatbonton T, Schuler AD, Posakony J, Li H, Goehle S, et al. Antitumor activity of a small-molecule inhibitor of human silent information regulator 2 enzymes. Cancer Res 2006; 66: 4368-77.
169. Brunet A, Sweeney LB, Sturgill JF, Chua KF, Greer PL, Lin Y, et al. Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase. Science. 2004; 303: 2011-5.
170. Min JR, Schuetz A, Allali-Hassan; A, Loppnau P, Kwiatkowski NP, Mazitschek R, et al. Catalytic domain of human histone deacetylase HDAC7.PDB ID 2NVR.
171. Min J, Schuetz A, Loppnau P, Weigelt J, Sundstrom M, Arrowsmith CH, et al. Crystal structure of human HDAC7 in complex with SAHA. PDB ID 2PQO.
172. Min J, Sch uetz A, Loppnau P, Weigelt J, Sundstrom M, Arrowsmith CH, et al. Crystal structure of human HDAC7 in complex with Trichostatin A (TSA). PDB ID 2PQP.
173. +-dependent deacetylase SIRT5 by suramm. Structure 2007; 15: 377-89.
174. Witter DJ, Harrington P, Wilson KJ, Chenard Ni, Fleming JC, Haines B, et al. Optimization of biary l selective HDAC 1 & 2 inhibitors (SHI-1:2)I Bioorg Med Chem LItt 2008; 18: in press (doi: i0.1016/ j.bmcl.23-07.11.047).
175. Methot JL, Chakravarty PK, Chenard M, Close J, Cruz JC, Dahlberg WK, et al. Exploration of the internal cavity of histone deacetylase (HDAC) with selective HDAC 1/HDAC 2 inhibitors (SHI-1:2). Bioorg Med Chem Lett 2008; 18: In press (doi: 10.1016/j. bmcl.2007.12.031).
176. Arts J, Angibaud P, Mariën A, Floren W, Janssens B, King P, et al. R306465 is a novel potent inhibitor of class 1 histone deacetylases with broad-spectrum antitumoral activity against solid and haomatological malignancies. Br J Cancer 2007; 97: 1344-53.
177. Schäfer S, Saunders L, Eliseeva E, Velena A, Jung M, Schwienhorst A, et al. Phenylalanine-containing hydroxamic acids as selective inhibitors of class IIb histone deacetylases (HDACs). Bioorg Med Chem 2008; 16: In press (doi: 10.1016/j.bmc.2007.10.092).
178. Boehrer S, Nowak D, Hoelzer D, Mitrou PS, Chow KU. Novel agents aiming at specific molecular targets increase chemosensitivity and overcome chemoresistance in hematopoietic malignancies. Curr Pharm Des 2006; 12(1): 111-28.
179. Elaut G, Rogiers V, Vanbaecke T. The pharmaceutical potential of historic deacetylase inhibitors. Curr Pharm Des 2007; 13(25): 2584-620.
180. Varier RA, Kundu TK. Chromatin modifications (acetylation/deacetylation/ methylation) as new targets for HIV therapy. Curr Pharm Des 2006; 12(16): 1975-93.